These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20621255)

  • 21. The dyslipidemia of chronic renal disease: effects of statin therapy.
    Ozsoy RC; van Leuven SI; Kastelein JJ; Arisz L; Koopman MG
    Curr Opin Lipidol; 2006 Dec; 17(6):659-66. PubMed ID: 17095911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic kidney disease and cardiovascular disease: a case presentation.
    McCarley PB; Salai PB
    Nephrol Nurs J; 2007; 34(2):187-98; quiz 199-200. PubMed ID: 17486949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.
    Nichols GA; Ambegaonkar BM; Sazonov V; Brown JB
    Am J Cardiol; 2009 Dec; 104(12):1689-94. PubMed ID: 19962476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beyond statin therapy: why we need new thinking.
    Assmann G
    Curr Med Res Opin; 2005; 21 Suppl 6():S3-8. PubMed ID: 16138935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treating dyslipidemia in the high-risk patient.
    Jones PH
    J Fam Pract; 2010 Feb; 59(2):E1. PubMed ID: 20141719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: The Lipid Treatment Assessment Project (L-TAP) 2.
    Santos RD; Waters DD; Tarasenko L; Messig M; Jukema JW; Ferrières J; Verdejo J; Chiang CW;
    Am Heart J; 2009 Nov; 158(5):860-6. PubMed ID: 19853709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The treatment of dyslipidemia--what's left in the pipeline?
    Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M
    ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipid abnormalities and cardiovascular risk in the elderly.
    Milionis HJ; Elisaf MS; Mikhailidis DP
    Curr Med Res Opin; 2008 Mar; 24(3):653-7. PubMed ID: 18218195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of coronary artery disease in patients with chronic kidney disease.
    Coats WC; Baig SZ; Alpert MA; Aggarwal K
    Adv Perit Dial; 2009; 25():125-8. PubMed ID: 19886333
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Model-based simulation to explore the cost-effectiveness of following practice guidelines for triglyceride and low-density lipoprotein cholesterol control among patients with diabetes mellitus and mixed dyslipidemia.
    Sorensen SV; Frick KD; Wade A; Simko R; Burge R
    Clin Ther; 2009 Apr; 31(4):862-79. PubMed ID: 19446159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
    McPherson R; Angus C; Murray P; Genest J;
    Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HMG CoA reductase inhibitors and renoprotection: the weight of the evidence.
    Romayne Kurukulasuriya L; Athappan G; Saab G; Whaley Connell A; Sowers JR
    Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):49-59. PubMed ID: 19124395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetes, cardiovascular risk and nephropathy.
    Hahr AJ; Molitch ME
    Cardiol Clin; 2010 Aug; 28(3):467-75. PubMed ID: 20621251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.